Login to Your Account

Other News To Note

Thursday, March 31, 2011
Regulus Therapeutics Inc., of La Jolla, Calif., gained exclusive rights from New York University (NYU) to intellectual property covering methods of use in modulating microRNA-33a (miR-33a) and miR-33b for metabolic diseases such as atherosclerosis and metabolic syndrome. Scientists from Regulus and NYU have shown that antagonizing miR-33a and miR-33b with therapeutic oligonucleotide anti-miRs had several beneficial effects, including reduction in atherosclerotic plaque and increase in levels of high-density lipoprotein.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription